Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Hübner, S. Korn, M. Jung, I. Haasler, C. Taube, R. Buhl (Mainz, Germany). Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma. Eur Respir J 2011; 38: Suppl. 55, 3352

Member's Comments

No comment yet.

Related content which might interest you: Allergic inflammation markers for earlier diagnosis of bronchial asthma in patients with allergic rhinitis Source: Annual Congress 2008 - Asthma: growing understanding of influential factors Year: 2008 Heterogeneous response of airway eosinophilia to biologics in severe asthma patients Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 IL-33 in patients with severe uncontrolled allergic asthma Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Markers of eosinophilic inflammation are associated with response to the DP2 antagonist GB001 in patients with mild atopic asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Airway inflammation in non-eosinophilic atopic asthma: comparisons with eosinophilic atopic asthma and COPD Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005 Clinical outcome of eosinophilic airway inflammation in chronic airway diseases including nonasthmatic eosinophilic bronchitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Factors driving airway eosinophilia in prednisone-dependent severe asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017 Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Markers of severity and inflammatory profile during exacerbations of severe asthma. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 Inflammatory profile of patients with allergic asthma & rhinitis versus patients with allergic rhinitis alone Source: Annual Congress 2007 - Mechanisms of inflammation in asthma and rhinitis - from cell cultures to patients Year: 2007 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Effects of formoterol-budesonide combination on residual eosinophilic inflammation in distal airway of patients with well-controlled moderate asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019